Mega to buy Bio-Life in B605m deal

Mega to buy Bio-Life in B605m deal

100% acquisition to drive regional growth

SET-listed Mega Lifesciences Plc, a pharmaceutical and food supplement company, has announced it will acquire Bio-Life Marketing Sdn, a Malaysian herbal medicine and food supplement company, for 605 million baht.

Mega yesterday signed a memorandum of understanding to buy 100% of Bio-Life's shares from DKSH Resources (Malaysia) Sdn. The acquisition will make Mega one of the top food supplement brands in Malaysia and help drive business growth in Southeast Asia.

"Malaysia is a sizeable market with strong economic fundamentals. Bio-Life has 25 years of history and is well-known as a scientifically proven food supplement brand. Additionally, its thinking and way of doing business fits with our philosophy," said Vivek Dhawan, chief executive of Mega Lifesciences.

"Bio-Life is a great company and Mega is glad to have it as a major part of our journey into Malaysia," he added.

Through this acquisition deal, Mega further aims to bring more focus to its over-the-counter food supplements and prescription products.

"In the future, this agreement will boost our plans to develop a wider range of food supplements and over-the-counter drugs in Malaysia. We're looking forward to having a successful future and strong brand with Bio-Life," said Mr Dhawan.

Mega aims to significantly boost market share and reach in Malaysia while additionally augmenting Mega's existing product lines with Bio-Life's product portfolio, which focuses on immune system support, general health, heart, eye and gut health, as well as a broad range of supplements.

Bio-Life is one of Mega's key planned investments to have taken place this year with an outlay of about 605 million baht.

Mr Dhawan noted that Mega plans to increase its investment in Maxxcare in Myanmar, which will be its second large-scale investment next year.

"Maxxcare will be integral to our plans to build a new state-of-the-art distribution centre for our products in Yangon, entailing an outlay of 389 million baht to be spent over 2017-18," he said.

Mega's revenue grew 5% to 6.21 billion baht in the first nine months of this year with a net profit of 500 million. Its total revenue was nearly 8.1 billion baht last year.

The company exports its products to 32 countries.

Bio-Life recorded sales of 427 million baht and a net profit of about 36 million in 2015.

Established in 1988 in Kuala Lumpur, Bio-Life is a leading local player with its business covering nutritional supplements and herbal remedies.

Its product categories include essential fatty acids, nutritional formulations, co-branded probiotics, herbal formulations and medicinal mushroom formulations.

MEGA shares closed yesterday on the Stock Exchange of Thailand at 22.50 baht, up 20 satang, in trade worth 194 million baht.

Do you like the content of this article?
COMMENT

China's Clover says its Covid booster shot candidate lifts antibody against Omicron

BEIJING: China's Clover Biopharmaceuticals said on Monday a booster shot of its Covid-19 vaccine candidate significantly increased antibody response against the Omicron coronavirus variant from levels seen after two primary shots.

19:05

Public eyes homes close to hospitals

The pandemic has shifted residential demand away from access to mass transit lines and towards hospitals as consumers prioritise healthcare services and wish to avoid crowded areas, according to a study.

18:33

109 live wild animals found in luggage at airport

Wildlife officials at Suvarnabhumi airport on Monday arrested two Indian women after 109 live wild animals were found in their baggage before they boarded a plane to India.

18:17